{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82","upperLimit":"96","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"OS was defined as the time from registration to death, or censored at last date known alive. Kaplan-Meier method was used to estimate the overall survival rate at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV on day 1 and paclitaxel IV and cetuximab IV on days 1, 8, and 15. Treatment repeats every 21 days for 3 courses. Patients then undergo evaluation of response to induction therapy. Patients with a CR at the primary tumor site proceed to group 1 of concurrent low-dose IMRT and cetuximab. Patients with a PR or SD at the primary tumor site or those with grossly positive disease at the primary tumor site proceed to group 2 of concurrent standard dose IMRT and cetuximab.","id":"OG000","title":"Eligible and Treated Patients"}],"paramType":"NUMBER","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"assessed within 14 days after delivery of the third cycle of induction therapy, and 8 weeks and 6 months after completion of concurrent therapy, then every 6 months until progression or until 3 years from study entry","title":"24-months Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}